お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はバイオ医薬品CDMO市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはバイオ医薬品CDMOの主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のバイオ医薬品CDMO市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはバイオ医薬品CDMOのメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にバイオ医薬品CDMO市場を分類しています。本研究に含まれる主な企業は：Lonza、Catalent、Samsung Biologics、FUJIFILM Diosynth Biotechnologies、Boehringer Ingelheim、WuXi AppTech、Recipharm、Thermo Fisher Scientific、AGC Biologics、Rentschler Biopharma、KBI Biopharma、Siegfried、Aenova Group、GenScript、ProBioGen、Northway Biotech、3P Biopharmaceuticals

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Cell and Gene Therapies
    Antibodies
    Vaccines
    Other

用途別の市場セグメント：
    SMBs
    Large Companies

本レポートの詳細内容
世界のバイオ医薬品CDMO市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、バイオ医薬品CDMOタイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のバイオ医薬品CDMO収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のバイオ医薬品CDMO市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、バイオ医薬品CDMO市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

バイオ医薬品CDMOのレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：バイオ医薬品CDMOのレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：バイオ医薬品CDMOの世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章バイオ医薬品CDMO企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：バイオ医薬品CDMOの各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：バイオ医薬品CDMOの主要企業の概要を提供し、製品の説明と仕様、バイオ医薬品CDMOの収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.
The global Biopharmaceutical CDMO market is projected to grow from US$ 28160 million in 2024 to US$ 59060 million by 2030, at a Compound Annual Growth Rate (CAGR) of 13.1% during the forecast period.
The core global biopharmaceutical CDMO manufacturers include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim and WuXi AppTech. The top three manufacturers account for approximately 37% of the global share. North America is the world's largest market, accounting for nearly 32% of the market share.
In terms of product type, antibodies occupy a dominant position, accounting for 36% of the market share. At the same time, in terms of application, large companies are the largest application field, accounting for 58%.
Report Includes
This report presents an overview of global market for Biopharmaceutical CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biopharmaceutical CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biopharmaceutical CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biopharmaceutical CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Biopharmaceutical CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Biopharmaceutical CDMO revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc.

Market Segmentation
By Company
    Lonza
    Catalent
    Samsung Biologics
    FUJIFILM Diosynth Biotechnologies
    Boehringer Ingelheim
    WuXi AppTech
    Recipharm
    Thermo Fisher Scientific
    AGC Biologics
    Rentschler Biopharma
    KBI Biopharma
    Siegfried
    Aenova Group
    GenScript
    ProBioGen
    Northway Biotech
    3P Biopharmaceuticals

Segment by Type
    Cell and Gene Therapies
    Antibodies
    Vaccines
    Other

Segment by Application
    SMBs
    Large Companies

By Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of South America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Biopharmaceutical CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biopharmaceutical CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biopharmaceutical CDMO revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
 Table 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of Cell and Gene Therapies
 Table 3. Key Players of Antibodies
 Table 4. Key Players of Vaccines
 Table 5. Key Players of Other
 Table 6. Global Biopharmaceutical CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Biopharmaceutical CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 8. Global Biopharmaceutical CDMO Market Size by Region (2019-2024) & (US$ Million)
 Table 9. Global Biopharmaceutical CDMO Market Share by Region (2019-2024)
 Table 10. Global Biopharmaceutical CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 11. Global Biopharmaceutical CDMO Market Share by Region (2025-2030)
 Table 12. Biopharmaceutical CDMO Market Trends
 Table 13. Biopharmaceutical CDMO Market Drivers
 Table 14. Biopharmaceutical CDMO Market Challenges
 Table 15. Biopharmaceutical CDMO Market Restraints
 Table 16. Global Biopharmaceutical CDMO Revenue by Players (2019-2024) & (US$ Million)
 Table 17. Global Biopharmaceutical CDMO Market Share by Players (2019-2024)
 Table 18. Global Top Biopharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2023)
 Table 19. Global Biopharmaceutical CDMO Industry Ranking 2022 VS 2023
 Table 20. Global 5 Largest Players Market Share by Biopharmaceutical CDMO Revenue (CR5 and HHI) & (2019-2024)
 Table 21. Global Key Players of Biopharmaceutical CDMO, Headquarters and Area Served
 Table 22. Global Key Players of Biopharmaceutical CDMO, Product and Application
 Table 23. Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 26. Global Biopharmaceutical CDMO Revenue Market Share by Type (2019-2024)
 Table 27. Global Biopharmaceutical CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 28. Global Biopharmaceutical CDMO Revenue Market Share by Type (2025-2030)
 Table 29. Global Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 30. Global Biopharmaceutical CDMO Revenue Market Share by Application (2019-2024)
 Table 31. Global Biopharmaceutical CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 32. Global Biopharmaceutical CDMO Revenue Market Share by Application (2025-2030)
 Table 33. North America Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 34. North America Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 35. North America Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 36. North America Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 37. North America Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 38. North America Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 39. North America Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 40. Europe Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 41. Europe Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 42. Europe Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 43. Europe Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 44. Europe Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 45. Europe Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 46. Europe Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 47. China Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 48. China Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 49. China Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 50. China Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 51. Asia Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 52. Asia Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 53. Asia Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 54. Asia Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 55. Asia Biopharmaceutical CDMO Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 56. Asia Biopharmaceutical CDMO Market Size by Region (2019-2024) & (US$ Million)
 Table 57. Asia Biopharmaceutical CDMO Market Size by Region (2025-2030) & (US$ Million)
 Table 58. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 59. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 60. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 61. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 62. Middle East, Africa, and Latin America Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 63. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 64. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 65. Lonza Company Details
 Table 66. Lonza Business Overview
 Table 67. Lonza Biopharmaceutical CDMO Product
 Table 68. Lonza Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 69. Lonza Recent Development
 Table 70. Catalent Company Details
 Table 71. Catalent Business Overview
 Table 72. Catalent Biopharmaceutical CDMO Product
 Table 73. Catalent Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 74. Catalent Recent Development
 Table 75. Samsung Biologics Company Details
 Table 76. Samsung Biologics Business Overview
 Table 77. Samsung Biologics Biopharmaceutical CDMO Product
 Table 78. Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 79. Samsung Biologics Recent Development
 Table 80. FUJIFILM Diosynth Biotechnologies Company Details
 Table 81. FUJIFILM Diosynth Biotechnologies Business Overview
 Table 82. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Product
 Table 83. FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 84. FUJIFILM Diosynth Biotechnologies Recent Development
 Table 85. Boehringer Ingelheim Company Details
 Table 86. Boehringer Ingelheim Business Overview
 Table 87. Boehringer Ingelheim Biopharmaceutical CDMO Product
 Table 88. Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 89. Boehringer Ingelheim Recent Development
 Table 90. WuXi AppTech Company Details
 Table 91. WuXi AppTech Business Overview
 Table 92. WuXi AppTech Biopharmaceutical CDMO Product
 Table 93. WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 94. WuXi AppTech Recent Development
 Table 95. Recipharm Company Details
 Table 96. Recipharm Business Overview
 Table 97. Recipharm Biopharmaceutical CDMO Product
 Table 98. Recipharm Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 99. Recipharm Recent Development
 Table 100. Thermo Fisher Scientific Company Details
 Table 101. Thermo Fisher Scientific Business Overview
 Table 102. Thermo Fisher Scientific Biopharmaceutical CDMO Product
 Table 103. Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 104. Thermo Fisher Scientific Recent Development
 Table 105. AGC Biologics Company Details
 Table 106. AGC Biologics Business Overview
 Table 107. AGC Biologics Biopharmaceutical CDMO Product
 Table 108. AGC Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 109. AGC Biologics Recent Development
 Table 110. Rentschler Biopharma Company Details
 Table 111. Rentschler Biopharma Business Overview
 Table 112. Rentschler Biopharma Biopharmaceutical CDMO Product
 Table 113. Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 114. Rentschler Biopharma Recent Development
 Table 115. KBI Biopharma Company Details
 Table 116. KBI Biopharma Business Overview
 Table 117. KBI Biopharma Biopharmaceutical CDMO Product
 Table 118. KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 119. KBI Biopharma Recent Development
 Table 120. Siegfried Company Details
 Table 121. Siegfried Business Overview
 Table 122. Siegfried Biopharmaceutical CDMO Product
 Table 123. Siegfried Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 124. Siegfried Recent Development
 Table 125. Aenova Group Company Details
 Table 126. Aenova Group Business Overview
 Table 127. Aenova Group Biopharmaceutical CDMO Product
 Table 128. Aenova Group Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 129. Aenova Group Recent Development
 Table 130. GenScript Company Details
 Table 131. GenScript Business Overview
 Table 132. GenScript Biopharmaceutical CDMO Product
 Table 133. GenScript Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 134. GenScript Recent Development
 Table 135. ProBioGen Company Details
 Table 136. ProBioGen Business Overview
 Table 137. ProBioGen Biopharmaceutical CDMO Product
 Table 138. ProBioGen Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 139. ProBioGen Recent Development
 Table 140. Northway Biotech Company Details
 Table 141. Northway Biotech Business Overview
 Table 142. Northway Biotech Biopharmaceutical CDMO Product
 Table 143. Northway Biotech Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 144. Northway Biotech Recent Development
 Table 145. 3P Biopharmaceuticals Company Details
 Table 146. 3P Biopharmaceuticals Business Overview
 Table 147. 3P Biopharmaceuticals Biopharmaceutical CDMO Product
 Table 148. 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
 Table 149. 3P Biopharmaceuticals Recent Development
 Table 150. Research Programs/Design for This Report
 Table 151. Key Data Information from Secondary Sources
 Table 152. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 2. Global Biopharmaceutical CDMO Market Share by Type: 2023 VS 2030
 Figure 3. Cell and Gene Therapies Features
 Figure 4. Antibodies Features
 Figure 5. Vaccines Features
 Figure 6. Other Features
 Figure 7. Global Biopharmaceutical CDMO Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 8. Global Biopharmaceutical CDMO Market Share by Application: 2023 VS 2030
 Figure 9. SMBs Case Studies
 Figure 10. Large Companies Case Studies
 Figure 11. Biopharmaceutical CDMO Report Years Considered
 Figure 12. Global Biopharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 13. Global Biopharmaceutical CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global Biopharmaceutical CDMO Market Share by Region: 2023 VS 2030
 Figure 15. Global Biopharmaceutical CDMO Market Share by Players in 2023
 Figure 16. Global Top Biopharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2023)
 Figure 17. The Top 10 and 5 Players Market Share by Biopharmaceutical CDMO Revenue in 2023
 Figure 18. North America Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 19. North America Biopharmaceutical CDMO Market Share by Type (2019-2030)
 Figure 20. North America Biopharmaceutical CDMO Market Share by Application (2019-2030)
 Figure 21. North America Biopharmaceutical CDMO Market Share by Country (2019-2030)
 Figure 22. United States Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 23. Canada Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Europe Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 25. Europe Biopharmaceutical CDMO Market Share by Type (2019-2030)
 Figure 26. Europe Biopharmaceutical CDMO Market Share by Application (2019-2030)
 Figure 27. Europe Biopharmaceutical CDMO Market Share by Country (2019-2030)
 Figure 28. Germany Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. France Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. U.K. Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Italy Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Russia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 33. Nordic Countries Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. China Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 35. China Biopharmaceutical CDMO Market Share by Type (2019-2030)
 Figure 36. China Biopharmaceutical CDMO Market Share by Application (2019-2030)
 Figure 37. Asia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Asia Biopharmaceutical CDMO Market Share by Type (2019-2030)
 Figure 39. Asia Biopharmaceutical CDMO Market Share by Application (2019-2030)
 Figure 40. Asia Biopharmaceutical CDMO Market Share by Region (2019-2030)
 Figure 41. Japan Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. South Korea Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 43. China Taiwan Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. Southeast Asia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 45. India Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. Australia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 47. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Type (2019-2030)
 Figure 49. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Application (2019-2030)
 Figure 50. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Country (2019-2030)
 Figure 51. Brazil Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 52. Mexico Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 53. Turkey Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 54. Saudi Arabia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 55. Israel Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 56. GCC Countries Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 57. Lonza Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 58. Catalent Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 59. Samsung Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 60. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 61. Boehringer Ingelheim Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 62. WuXi AppTech Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 63. Recipharm Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 64. Thermo Fisher Scientific Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 65. AGC Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 66. Rentschler Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 67. KBI Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 68. Siegfried Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 69. Aenova Group Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 70. GenScript Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 71. ProBioGen Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 72. Northway Biotech Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 73. 3P Biopharmaceuticals Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024)
 Figure 74. Bottom-up and Top-down Approaches for This Report
 Figure 75. Data Triangulation
 Figure 76. Key Executives Interviewed